Orforglipron May Offer an Alternative to Weekly Injections Marilyn Tan, MD, a clinical associate professor of medicine specializing in endocrinology, gerontology, and metabolism at Stanford University in California, notes that the GLP-1 pill Rybelsus is already available, but only approved by the U.S
Early-phase clinical trial data, including results from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), demonstrated significant weight reduction in adults with obesity (without type 2 diabetes), with participants receiving the highest dose losing a mean of approximately 24% of their body weight over 48 weeks
In silico analysis of exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome
Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, and Genest J Jr (1996)
Convenient Prescription Services: LifeRx.md simplifies obtaining your GLP-1 prescription with telemedicine consultations and direct delivery services
Research comparing various weight loss interventions shows similar patterns of body composition change